Binds Lymphocytic Or Lymphocytic-like Cell Or Component Or Product Thereof (e.g., B Cell, B-lineage Bone Marrow Cell, Null Cell, Natural Killer Cell, B-lymphoblastoid Cell, B-lineage Acute Lymphoblastic Leukemia Cell, B-lymphocytic Cell-surface Antigen, Etc.) Patents (Class 530/388.73)
-
Patent number: 11702478Abstract: The present invention relates to humanized monoclonal antibodies or antigen-binding fragments thereof that specifically bind to human CD40 receptor and induce CD40 signaling independent of Fey mediated CD40 receptor crosslinking. The antibodies of the present invention bind to a CD40 epitope that overlaps with the epitope of the CD40 ligand and can activate human APCs. The present invention also provides for compositions comprising said antibodies and uses for the antibodies and compositions in the treatment of patients suffering from cancer.Type: GrantFiled: September 19, 2018Date of Patent: July 18, 2023Assignee: MAB DISCOVERY GMBHInventors: Stephan Fischer, Karsten Beckmann
-
Patent number: 11639384Abstract: This disclosure provides a method for treating a pediatric subject afflicted with acute B cell precursor leukemia (BCP-ALL) comprising administering to the subject an anti-killer cell immunoglobulin-like receptor (KIR) antibody or an antigen-binding portion thereof that binds specifically to an inhibitory KIR and blocks inhibitory KIR activity, thereby potentiating NK cell lytic activity. An exemplary anti-KIR antibody for use in this method is lirilumab. The disclosure also provides a kit for treating a subject afflicted with pediatric BCP-ALL, the kit comprising a dosage ranging from 0.01 to 20 mg/kg body weight of an anti-KIR antibody or an antigen-binding portion thereof that specifically binds to an inhibitory KIR and blocks inhibitory KIR activity, and instructions for using the anti-KIR antibody or an antigen-binding portion thereof in any of the disclosed methods for treating pediatric BCP-ALL.Type: GrantFiled: October 27, 2015Date of Patent: May 2, 2023Assignee: University Children's Hospital TübingenInventors: Maya Caroline André, Ayline Kübler
-
Patent number: 10765699Abstract: The present invention relates to a method of using a receptor (e.g., chimeric antigen receptor—CAR) that activates an immune response upon binding a cancer cell ligand in conjunction with a target-binding molecule that targets a protein or molecule CI for removal or neutralization to generate enhanced anti-cancer immune cells. The present invention also relates to engineered immune cells having enhanced therapeutic efficacy and uses thereof.Type: GrantFiled: February 5, 2016Date of Patent: September 8, 2020Assignee: National University of SingaporeInventors: Dario Campana, Takahiro Kamiya
-
Patent number: 10544229Abstract: The present invention relates to agonistic antibodies specifically binding human CD40, polynucleotides encoding the antibodies or antigen-binding fragments, and methods of making and using the foregoing.Type: GrantFiled: September 30, 2016Date of Patent: January 28, 2020Assignee: Janssen Biotech, Inc.Inventors: Johan Fransson, Paul Kim, Michael Quigley, Andressa Smith, Alexey Teplyakov, Hong Zhou
-
Patent number: 9365637Abstract: The present invention provides: a novel antiviral agent containing a human antibody ? light chain, a novel human abzyme containing a human antibody ? light chain; a polynucleotide, a vector, and a transformant, encoding a human antibody ? light chain of the above; a primer set for effectively obtaining a human antibody ? light chain having a function as an antiviral agent or abzyme; and a method for producing a polynucleotide and a method for producing a polypeptide, each of which method utilizes the primer set.Type: GrantFiled: February 21, 2011Date of Patent: June 14, 2016Assignee: JAPAN SCIENCE AND TECHNOLOGY AGENCYInventors: Taizo Uda, Emi Hifumi, Akira Nishizono, Mitsue Arakawa
-
Patent number: 9028824Abstract: The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.Type: GrantFiled: May 17, 2012Date of Patent: May 12, 2015Assignees: Pfizer Inc., Bristol-Myers Squibb CompanyInventors: Jing Min, Yanli Wu, Rory F. Finn, Barrett R. Thiele, Wei Liao, Ronald P. Gladue, Arvind Rajpal, Timothy J. Paradis, Peter Brams, Brigitte Devaux, Yi Wu, Kristopher Toy, Heidi N. LeBlanc, Haichun Huang
-
Patent number: 9028826Abstract: Improved anti-CD154 antibodies are provided herein which have ablated FcR binding and/or complement binding/activation. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation and allergic disorders is disclosed herein.Type: GrantFiled: March 13, 2013Date of Patent: May 12, 2015Assignee: The Trustees of Dartmouth CollegeInventor: Randolph J. Noelle
-
Publication number: 20150118750Abstract: A composition-of-matter comprising an antibody or antibody fragment including an antigen-binding region capable of specifically binding an antigen-presenting portion of a complex composed of a human antigen-presenting molecule and an antigen derived from a pathogen is disclosed.Type: ApplicationFiled: January 12, 2015Publication date: April 30, 2015Applicant: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITEDInventors: Yoram REITER, Cyril COHEN
-
Patent number: 9000133Abstract: This application provides methods and compositions for modulating and/or depleting CD200 positive cells.Type: GrantFiled: February 20, 2013Date of Patent: April 7, 2015Assignee: Alexion Pharmaceuticals, Inc.Inventors: Katherine S. Bowdish, Anke Kretz-Rommel, Susan Faas McKnight, Jeremy P. Springhorn, Dayang Wu
-
Patent number: 8993730Abstract: This invention relates to chimeric and humanized antibodies that specifically bind the BCR complex, and particularly chimeric and humanized antibodies to the BCR complex. The invention also relates to methods of using the antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.Type: GrantFiled: September 23, 2013Date of Patent: March 31, 2015Assignee: MacroGenics, Inc.Inventors: Leslie S. Johnson, Ling Huang
-
Patent number: 8987422Abstract: The present invention relates to CD27L antigen binding proteins, such an antibodies, polynucleotides encoding said CD27l antigen binding proteins, antibody drug conjugate compositions, and methods for diagnosing and treating diseases associated with CD27L expression.Type: GrantFiled: September 20, 2012Date of Patent: March 24, 2015Assignee: Amgen Inc.Inventors: John M. Delaney, William Christian Fanslow, III, Chadwick Terence King
-
Patent number: 8981065Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.Type: GrantFiled: July 8, 2013Date of Patent: March 17, 2015Assignees: Novo Nordisk A/S—Novo Alle, Innate Pharma S.A.S., University of GenoaInventors: Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurent Gauthier, Francois Romagne, Peter Andreas Nicolai Reumert Wagtmann, Ivan Svendsen, Stefan Zahn, Anders Svensson, Matthias Thorolfsson, Soren Berg Padkaer, Kristian Kjaergaard, Pieter Johannes Louis Spee, Michael Wilken
-
Patent number: 8961976Abstract: The present invention provides peptides, and fragments thereof, and antibodies, or fragments thereof comprising the same, wherein the peptide comprises at least one amino acid substitution compared to wild type 5c8 antibody. The present invention also provides compositions and methods of treating CD154-related diseases or disorders in a subject.Type: GrantFiled: December 19, 2013Date of Patent: February 24, 2015Assignee: Biogen Idec Ma Inc.Inventors: Herman Van Vlijmen, Alexey Lugovskoy, Karl Hanf
-
Patent number: 8962806Abstract: The present invention comprises a humanized monoclonal antibody that binds to the chemokine receptor CCR4. This antibody is derived from Mab 1567 and recognizes the same epitope. Binding of the invented antibody to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells.Type: GrantFiled: December 29, 2008Date of Patent: February 24, 2015Assignees: Dana-Farber Cancer Institute, Inc., The Bingham and Women's HospitalInventors: Wayne Marasco, Jianhua Sui, Quan Zhu, Thomas Kupper
-
Patent number: 8946387Abstract: The present invention relates to antibodies or fragments thereof that specifically bind Fc?RIIB, particularly human Fc?RIIB, more particularly the extracellular domain of Fc?RIIB with greater affinity than said antibodies or fragments thereof bind Fc?RIIA, particularly human Fc?RIIA, and block the Fc binding site of Fc?RIIB. The present invention also encompasses the use of an anti-Fc?RIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The present invention also encompasses the use of an anti-Fc?RIIB antibody or an antigen-binding fragment thereof, in combination with other cancer therapies.Type: GrantFiled: August 5, 2008Date of Patent: February 3, 2015Assignee: MacroGenics, Inc.Inventors: Scott Koenig, Maria Concetta Veri, Nadine Tuaillon, Ezio Bonvini
-
Patent number: 8926979Abstract: Methods for treating a human patient for a cancer or pre-malignant condition that is associated with CD40-expressing cells are provided, where the human patient is heterozygous or homozygous for Fc?RIIIa-158F (genotype V/F or F/F). Also provided are methods of inhibiting antibody production by B cells in a human patient who is heterozygous or homozygous for Fc?RIIIa-158F (genotype V/F or F/F). The methods comprise administering to the human patient a therapeutically or prophylactically effective amount of an anti-CD40 antibody. Methods and kits for identifying a human patient with a cancer or pre-malignant condition that is treatable with an anti-CD40 antibody and which is refractory to treatment with rituximab (Rituxan®), as well as methods and kits for selecting an antibody therapy for treatment of a human patient having a cancer or pre-malignant condition that is refractory to treatment with rituximab (Rituxan®), are also provided.Type: GrantFiled: November 1, 2006Date of Patent: January 6, 2015Assignees: Novartis AG, XOMA Technology Ltd.Inventors: Sharon Lea Aukerman, Mohammad Luqman
-
Patent number: 8911726Abstract: A highly stable mutant of human IgG4 antibody is provided. Such antibody is an antibody in which the CH3 domain of human IgG4 is substituted with the CH3 domain of human IgG1 and which exhibits inhibited aggregate formation, an antibody in which the CH3 and CH2 domains of human IgG4 are substituted with the CH3 and CH2 domains of human IgG1, respectively, or an antibody in which arginine at position 409 indicated in the EU index proposed by Kabat et al. of human IgG4 is substituted with lysine and which exhibits inhibited aggregate formation.Type: GrantFiled: September 22, 2005Date of Patent: December 16, 2014Assignee: Kyowa Hakko Kirin Co., LtdInventors: Nobuaki Takahashi, Hideaki Yoshida
-
Patent number: 8895010Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.Type: GrantFiled: October 12, 2012Date of Patent: November 25, 2014Assignees: Bristol-Myers Squibb Company, Domantis LimitedInventors: Steven G. Nadler, James K. Tamura, Laura Price, Robert P. Rehfuss, Suzanne J. Suchard, Anish Suri, James William Bryson, Aaron Yamniuk, Steven Grant, Olga Ignatovich, Philip Drew
-
Patent number: 8883980Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.Type: GrantFiled: August 17, 2007Date of Patent: November 11, 2014Assignee: Roche Glycart AGInventors: Pablo Umaña, Peter Brünker, Claudia Ferrera Koller, Tobias Suter, Ursula Püntener, Ekkehard Mössner
-
Patent number: 8853363Abstract: The invention relates to novel immunogens carrying conformationally discriminating epitopes (CDEs) and to immunization methods for producing antibodies that specifically recognize proteins with very closely related homologues. In particular, the invention relates to antibodies which are specific for either Fc?RIIb or Fc?RIIa.Type: GrantFiled: November 26, 2004Date of Patent: October 7, 2014Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.Inventors: Robert Huber, Peter Sondermann, Uwe Jacob, Kerstin Wendt, Chiara Cabrele, Luis Moroder
-
Patent number: 8852597Abstract: Improved anti-CD154 antibodies are provided herein which have ablated FcR binding. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation and allergic disorders is disclosed herein.Type: GrantFiled: April 4, 2012Date of Patent: October 7, 2014Assignee: The Trustees of Dartmouth CollegeInventor: Randolph J. Noelle
-
Patent number: 8846045Abstract: The present invention concerns human antibodies recognizing the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.Type: GrantFiled: June 18, 2013Date of Patent: September 30, 2014Assignee: Novo Nordisk A/SInventors: Kristian Kjaergaard, Soeren Lund
-
Patent number: 8828396Abstract: The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.Type: GrantFiled: November 14, 2011Date of Patent: September 9, 2014Assignee: Novartis AGInventors: Christoph Heusser, James Rush, Karen Vincent
-
Patent number: 8828397Abstract: Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of inducing death of an activated T-cell and of modulating a T cell-mediated immune response in a subject.Type: GrantFiled: September 14, 2012Date of Patent: September 9, 2014Assignee: AbGenomics Cooperatief U.A.Inventors: Rong-Hwa Lin, Chung Nan Chang, Pei-Jiun Chen, Chiu-Chen Huang
-
Patent number: 8828394Abstract: This invention relates to methods of treating IgE mediated disorders such as allergy and asthma based on activating surface-bound IgD molecules on basophils. The invention also relates to methods of making IgD, as well as methods of screening for antimicrobial agents from IgD-activated basophils.Type: GrantFiled: April 1, 2010Date of Patent: September 9, 2014Assignee: Cornell UniversityInventors: Andrea Cerutti, Kang Chen
-
Patent number: 8815242Abstract: The invention is drawn to a composition comprising an isolated mixture of cytotoxic anti-CD20 antibody molecules produced in a transgenic avian. The antibody molecules have a heavy chain and a light chain whose amino acid sequences set forth in SEQ ID NOs: 4 and 5 and exhibit an increased level of cytotoxicity as compared to anti-CD20 antibody molecules produced in CHO cells.Type: GrantFiled: May 27, 2010Date of Patent: August 26, 2014Assignee: Synageva BioPharma Corp.Inventor: Alex J. Harvey
-
Publication number: 20140234867Abstract: Isolated antibodies specifically binding to heterodimers of the Bcl-2 family and uses thereof for detecting presence of Bcl-2 heterodimers in a patient.Type: ApplicationFiled: April 30, 2014Publication date: August 21, 2014Applicant: Eutropics Pharmaceuticals, Inc.Inventors: Michael H. Cardone, Anthony G. Letai
-
Patent number: 8779108Abstract: Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.Type: GrantFiled: November 24, 2010Date of Patent: July 15, 2014Assignee: MedImmune, LimitedInventors: Christophe Queva, Michelle Morrow, Scott Hammond, Marat Alimzhanov, John Babcook, Ian Nevin Foltz, Jaspal Singh Kang, Laura Sekirov, Melanie Boyle, Matthieu Chodorge, Ross A. Stewart, Kathleen Ann Mulgrew
-
Patent number: 8778345Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.Type: GrantFiled: April 27, 2012Date of Patent: July 15, 2014Assignee: Apexigen, Inc.Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
-
Patent number: 8735545Abstract: The present invention relates to Fc variants having increased affinity for Fc?RIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.Type: GrantFiled: June 19, 2007Date of Patent: May 27, 2014Assignee: Xencor, Inc.Inventors: Gregory Alan Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
-
Patent number: 8722857Abstract: The present invention is directed to cysteine-engineered anti-CD79b antibody, huMA79b.v28, and compositions of matter thereof useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.Type: GrantFiled: January 14, 2009Date of Patent: May 13, 2014Assignee: Genentech, Inc.Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson
-
Patent number: 8691952Abstract: Anti-CD19 B4 antibodies with modified variable regions are disclosed. The modified anti-CD19 variable region polypeptides have alterations to one or more framework regions or complementarity determining regions of the heavy chain variable region or light chain variable region, thereby to reduce a T-cell response.Type: GrantFiled: December 29, 2006Date of Patent: April 8, 2014Assignee: Merck Patent GmbHInventors: Michael Super, Jonathan Davis, Pascal André Stein
-
Patent number: 8686119Abstract: The present invention relates to humanized monoclonal antibodies, pharmaceutical compositions that include the same, and use thereof for the treatment of a variety of indications, particularly cancer and immunodeficiency disorders. In particular, the present invention provides modified antibodies or fragments thereof having specific amino acid modifications compared to the humanized monoclonal immunomodulatory antibody termed hBAT-1.Type: GrantFiled: July 23, 2012Date of Patent: April 1, 2014Assignee: CureTech Ltd.Inventors: Rinat Rotem-Yehudar, Michael Schickler
-
Patent number: 8679500Abstract: The present invention relates to compositions containing antibodies for treating CD5+ HLA-DR+ B OR T cell related diseases such as B or T cell malignances (leukaemia and lymphoma), autoimmune diseases and T cell related diseases as transplantation and graft rejection.Type: GrantFiled: May 14, 2010Date of Patent: March 25, 2014Assignees: Institute National de la Sante et de la Recherche Medicale (INSERM), Universite de Bretagne Occidentale, Centre National de la Recherche Scientifique (CNRS)Inventors: Laurence Boumsell, Christian Berthou, Karine Lester, Severine Loisel, Martine Cerruti
-
Patent number: 8669352Abstract: The present invention provides novel antagonistic anti-human CD40 monoclonal antibodies, methods for generating them and uses thereof.Type: GrantFiled: May 9, 2007Date of Patent: March 11, 2014Assignee: Fast Forward Pharmaceuticals B.V.Inventors: Marcel Theodorus den Hartog, Ruprecht Jules Joost van Neerven, Kevin Stuart Johnson, Robert Duncan Casson
-
Patent number: 8663641Abstract: Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of inducing death of an activated T-cell and of modulating a T cell-mediated immune response in a subject.Type: GrantFiled: September 14, 2012Date of Patent: March 4, 2014Assignee: AbGenomics Cooperatief U.A.Inventors: Rong-Hwa Lin, Chung Nan Chang, Pei-Jiun Chen, Chiu-Chen Huang
-
Patent number: 8647625Abstract: The present invention provides peptides, and fragments thereof, and antibodies, or fragments thereof comprising the same, wherein the peptide comprises at least one amino acid substitution compared to wild type 5c8 antibody. The present invention also provides compositions and methods of treating CD154-related diseases or disorders in a subject.Type: GrantFiled: July 26, 2005Date of Patent: February 11, 2014Assignee: Biogen Idec MA Inc.Inventors: Herman Van Vlijmen, Alexey Alexandrovic Lugovskoy, Karl J. M. Hanf
-
Patent number: 8648171Abstract: The invention relates to members of the Fc receptor homolog (FcRH) subfamily, as well as fragments and variants thereof. Each FcRH is a Type I transmembrane receptor, preferably, comprises an extracellular region, a transmembrane region, and a cytoplasmic region. The cytoplasmic region preferably comprises one or more immunoreceptor tyrosine-based inhibitory or activation motifs (“ITIMs” or “ITAMs). The invention provides polypeptides, nucleic acids, vectors, expression systems, and antibodies and antibody fragments related to the FcRHs as well as uses thereof. Such uses include uses in the diagnosis and treatment of a malignancy of hematopoietic cell lineage or an inflammatory or autoimmune disease in a subject and in the modulation of a humoral immune response in a subject.Type: GrantFiled: August 7, 2007Date of Patent: February 11, 2014Assignee: The UAB Research FoundationInventors: Randall S. Davis, Max D. Cooper
-
Patent number: 8637032Abstract: Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.Type: GrantFiled: September 12, 2012Date of Patent: January 28, 2014Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Li Long, Asha Yabannavar, Isabel Zaror, Sang Hoon Lee, Deborah Hurst
-
Patent number: 8637641Abstract: The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. increased serum half-life in vivo.Type: GrantFiled: July 29, 2011Date of Patent: January 28, 2014Assignee: Xencor, Inc.Inventors: Bassil I. Dahiyat, Gregory A. Lazar, Matthew J. Bernett
-
Patent number: 8624001Abstract: The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases. In more particular embodiments, the humanized anti-CD 19 antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels. In a particularly preferred embodiment, the substitutions comprise a Ser91Phe substitution in the hAl9 VH sequence.Type: GrantFiled: June 17, 2013Date of Patent: January 7, 2014Assignee: Immunomedics, Inc.Inventors: Hans J. Hansen, Zhengxing Qu, David M. Goldenberg
-
Patent number: 8617554Abstract: The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a humanized immunoglobulin or immunoglobulin light chain or heavy chain, and to a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in therapeutic applications to treat, for example, autoimmune disease, cancer, non-Hodgkin's lymphoma, multiple sclerosis and chronic lymphocytic leukemia.Type: GrantFiled: May 13, 2010Date of Patent: December 31, 2013Assignee: Genzyme CorporationInventors: Bruce L Roberts, Srinivas Shankara, William Harold Brondyk, William M Siders
-
Patent number: 8613916Abstract: The present invention provides an immunotherapeutic agent and immunotherapy allowing the extension of the survival time of patients with pancreatic cancer. The immunotherapy of the present invention is characterized by comprising the steps of culturing peripheral blood lymphocytes of a patient with pancreatic cancer by stimulating the lymphocytes with an anti-CD3 antibody and an anti-CD52 antibody, thereby to obtain an immunotherapeutic agent, and administering at least four infusions of the resultant immunotherapeutic agent to the same patient, wherein each of the infusions of the immunotherapeutic agent comprises at least 15×109 cells of activated lymphocytes, the percentage of CD3? CD56+ NK cells in the activated lymphocytes is at least 30%, and the administration of the immunotherapeutic agent is begun for the patient who is in at least one state of two or more particular immunocompromised states.Type: GrantFiled: October 6, 2009Date of Patent: December 24, 2013Assignee: Cellex CorporationInventor: Jun-ichi Masuyama
-
Patent number: 8613926Abstract: The present invention concerns human antibodies recognizing the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.Type: GrantFiled: June 6, 2012Date of Patent: December 24, 2013Assignee: Novo Nordisk A/SInventors: Kristian Kjaergaard, Soeren Lund, Soeren Berg Padkjaer
-
Patent number: 8609100Abstract: A cell surface molecule designated DCIR (for dendritic cells ImmunoReceptor), a member of a recently described family of DC-expressing C-type lectin receptors, has been shown to participate to the capture of human immunodeficiency virus (HIV) and promote infection in trans and in cis of autologous CD4(+) T cells from human immature monocyte-derived DC. The contribution of DCIR to these processes was revealed using DCIR-specific siRNAs and a polyclonal antibody specific for the carbohydrate recognition domain of DCIR. Therapeutic agents for HIV infection are therefore provided herein. These therapeutic agents are useful for impairing the interaction between DCIR and HIV and as such may be useful for treatment or prevention of HIV infection. Also provided are assays for identifying additional therapeutics agents for treatment or prevention HIV infection.Type: GrantFiled: October 24, 2011Date of Patent: December 17, 2013Assignee: Universite LavalInventors: Alexandra Lambert, Caroline Gilbert, Michel J. Tremblay
-
Patent number: 8597659Abstract: The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-MAb DNL complex comprises an IgG antibody attached to two AD (anchor domain) moieties and four cytokines, each attached to a DDD (docking and dimerization domain) moiety. The DDD moieties form dimers that bind to the AD moieties, resulting in a 2:1 ratio of DDD to AD. The cytokine-MAb complex exhibits improved pharmacokinetics, with a significantly longer serum half-life than either naked cytokine or PEGylated cytokine. The cytokine-MAb complex also exhibits significantly improved in vitro and in vivo efficacy compared to cytokine alone, antibody alone, unconjugated cytokine plus antibody or cytokine-MAb DNL complexes incorporating an irrelevant antibody. In more preferred embodiment the cytokine is G-CSF, erythropoietin or INF-?2b.Type: GrantFiled: August 29, 2011Date of Patent: December 3, 2013Assignee: IBC Pharmaceuticals, Inc.Inventors: Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi
-
Antibodies Directed Against HLA-B27 Homodimers and Methods and Uses Thereof in Diagnosis and Therapy
Publication number: 20130315933Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to HLA-B27 heavy-chain homodimers, termed HC-B27, HLA-B272 or B272, particularly recognizing B272 homodimers and which do not recognize or bind HLA-B27 heterotrimers (B27) including HLA-B27 heterotrimers with ?2 microglobulin and peptide. These antibodies are useful in the diagnosis and treatment of HLA-B27 mediated conditions, particularly those associated with B272, the spondylarthritides, a group of related diseases including ankylosing spondylitis (AS) and reactive arthritis (ReA or Reiter's syndrome). The antibodies, variable regions or CDR domain sequences thereof, and fragments thereof of the present invention may also be used in therapy in combination with chemotherapeutics, immune modulators, anti-inflammatory drugs, NSAIDs and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies HD4, HD5 and HD6 whose sequences are provided herein.Type: ApplicationFiled: October 6, 2011Publication date: November 28, 2013Inventors: Christoph Renner, Andreas Wadle, Sravan Payeli, Markus Thiel, Paul Bowness, Simon Kollnberger -
Patent number: 8591900Abstract: The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.Type: GrantFiled: March 30, 2011Date of Patent: November 26, 2013Assignee: Boehringer Ingelheim International GmbHInventors: Rachel Rebecca Barrett, Scott Ronald Brodeur, Keith Canada, Tobias Litzenburger, Sanjaya Singh
-
Patent number: 8568725Abstract: A mutant of a potentially therapeutic anti-CD40 antibody is provided which mutant has reduced ADCC and CDC activities designed to be optimized as a pharmaceutical agent. A mutant of an agonistic anti-CD40 antibody, comprising mutation and/or substitution of at least one amino acid in the constant region to reduce the ADCC and/or CDC activities therein, and a mutant of an antagonistic anti-CD40 antibody, comprising at least one mutation or substitution in the constant region to reduce the ADCC and/or CDC activities therein, both mutants having at least a hinge region derived from a human IgG2.Type: GrantFiled: December 24, 2004Date of Patent: October 29, 2013Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Nobuaki Takahashi, Toru Miura, Yoshinori Kitagawa, Aki Hirano
-
Patent number: 8551485Abstract: The present invention describes humanized antibodies that target CD40, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.Type: GrantFiled: January 21, 2009Date of Patent: October 8, 2013Assignee: Xencor, Inc.Inventors: Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik WeiKing Pong, Eugene Alexander Zhukovsky